CBD and Dog Seizures: Dosing & Protocol
By Will Scott | Published April 23, 2026
Epilepsy is one of the most common neurological disorders in dogs, affecting an estimated 0.5-5% of the canine population depending on breed. For dogs with epilepsy, recurrent seizures disrupt normal life, cause significant distress for both dog and owner, and in severe cases can lead to brain damage or death from status epilepticus (prolonged, continuous seizures). Traditional anti-epileptic drugs like phenobarbital and potassium bromide are effective for many dogs but come with significant side effects including sedation, increased thirst and urination, liver toxicity, and in some cases, inadequate seizure control even at maximum doses. Approximately 30% of dogs with epilepsy are considered drug-resistant or refractory, meaning conventional medications fail to adequately control their seizures. For these dogs and their owners, the search for additional treatment options is urgent and often desperate.
CBD has emerged as a promising adjunct therapy for canine epilepsy, supported by landmark research from Colorado State University that demonstrated significant seizure reduction in dogs receiving CBD alongside conventional anti-epileptic drugs. The 2019 study, published in the Journal of the American Veterinary Medical Association, found that 89% of dogs receiving CBD experienced a reduction in seizure frequency, with an average reduction of 33% compared to placebo. This research represents the first controlled clinical trial of CBD for canine epilepsy and provides the evidence-based foundation for using CBD as part of a comprehensive seizure management protocol. While CBD is not a cure for epilepsy and should not replace conventional anti-epileptic medications, it offers a valuable tool for improving seizure control, potentially reducing medication doses and side effects, and enhancing quality of life for dogs with epilepsy.
This comprehensive guide examines the evidence for CBD in canine epilepsy, from the mechanisms by which CBD reduces seizure activity to the specific dosing protocols validated by research. We'll explore how CBD interacts with conventional anti-epileptic drugs, what to expect in terms of seizure reduction and timeline for effects, how to monitor response and adjust treatment, and realistic expectations about what CBD can and cannot accomplish for dogs with seizures. The goal is to provide evidence-based guidance that helps you and your veterinarian determine whether CBD might benefit your dog's seizure control and how to integrate it safely and effectively into a comprehensive epilepsy management plan. Understanding both the promise and limitations of CBD for seizures is essential for making informed treatment decisions and achieving the best possible outcomes for your dog.
Understanding Canine Epilepsy and Seizures
To understand how CBD might help control seizures, it's essential to first understand what causes seizures and how they manifest in dogs. A seizure is a sudden, uncontrolled electrical disturbance in the brain that causes changes in behavior, movements, feelings, and levels of consciousness. In dogs, seizures typically manifest as convulsions with loss of consciousness, muscle rigidity or paddling movements, loss of bladder or bowel control, excessive salivation, and temporary confusion or disorientation after the seizure ends (the post-ictal period). However, seizures can also be more subtle, presenting as focal seizures affecting only part of the body or causing behavioral changes like fly-biting, staring, or unusual vocalizations without full-body convulsions.
Types of Canine Epilepsy
Canine epilepsy is classified into several categories based on underlying cause. Idiopathic epilepsy, also called primary or genetic epilepsy, has no identifiable structural brain abnormality and is believed to result from genetic predisposition affecting neuronal excitability. This is the most common form of epilepsy in dogs, typically beginning between 6 months and 6 years of age, and is particularly prevalent in certain breeds including Border Collies, Australian Shepherds, Beagles, Belgian Tervurens, and German Shepherds. Idiopathic epilepsy is the type most studied in CBD research and appears to respond best to CBD treatment.
Structural epilepsy results from identifiable brain abnormalities including brain tumors, stroke, trauma, inflammatory brain disease (encephalitis), or congenital malformations. Seizures from structural causes typically begin later in life (after 6 years of age) or very early (before 6 months), and the seizure pattern may be focal rather than generalized. Structural epilepsy often requires treatment of the underlying cause in addition to anti-epileptic medications, and response to CBD may be less consistent than with idiopathic epilepsy. Reactive seizures occur in response to metabolic disturbances like low blood sugar (hypoglycemia), liver disease (hepatic encephalopathy), kidney failure, or toxin exposure. These seizures resolve when the underlying metabolic problem is corrected and don't represent true epilepsy, though CBD might provide some benefit during the acute phase.
Visual representation of the dichotomy of the neuronal activity present both during a seizure and baseline
The Neurobiology of Seizures
Normal brain function requires a precise balance between excitatory neurotransmitters (like glutamate) that activate neurons and inhibitory neurotransmitters (like GABA) that suppress neuronal activity. Seizures occur when this balance is disrupted, with excessive excitation or insufficient inhibition leading to synchronized, uncontrolled electrical discharges across large populations of neurons. In epilepsy, various factors can lower the seizure threshold—the point at which normal brain activity tips into seizure activity. These factors include genetic mutations affecting ion channels that control neuronal excitability, inflammation in the brain that increases neuronal sensitivity, imbalances in neurotransmitter systems, and structural abnormalities that create abnormal electrical circuits.
The endocannabinoid system plays an important role in regulating neuronal excitability and seizure threshold. CB1 receptors are highly expressed in the brain, particularly in areas involved in seizure generation like the hippocampus and cortex. Endocannabinoids act as retrograde messengers—when a neuron becomes overexcited, it releases endocannabinoids that travel backward across the synapse and activate CB1 receptors on the presynaptic neuron, reducing further neurotransmitter release. This negative feedback mechanism helps prevent excessive neuronal excitation and may represent the brain's natural anti-seizure system. Research suggests that endocannabinoid deficiency or dysfunction may contribute to epilepsy, and that enhancing endocannabinoid signaling through CBD might help restore normal seizure threshold.
Conventional Anti-Epileptic Treatment
The standard approach to treating canine epilepsy involves anti-epileptic drugs (AEDs) that work through various mechanisms to reduce neuronal excitability and raise seizure threshold. Phenobarbital is the most commonly used first-line AED in dogs, working by enhancing GABA-mediated inhibition and reducing neuronal excitability. It's effective for 60-80% of dogs with idiopathic epilepsy but causes significant side effects including sedation, increased appetite and thirst, increased urination, and potential liver toxicity with long-term use. Blood level monitoring is required to maintain therapeutic levels while avoiding toxicity.
Potassium bromide is often used as a second-line AED or in combination with phenobarbital for dogs with inadequate seizure control. It works by competing with chloride ions to hyperpolarize neurons, making them less likely to fire. Side effects include sedation, increased thirst and urination, and potential pancreatitis, particularly in dogs on high-fat diets. Levetiracetam (Keppra) is a newer AED that modulates neurotransmitter release and is often used as add-on therapy for refractory epilepsy. It has fewer side effects than phenobarbital or bromide but is less effective as monotherapy and requires dosing three times daily. Zonisamide is another newer AED that works through multiple mechanisms and is used for refractory epilepsy, though it's more expensive and requires twice-daily dosing.
Despite these treatment options, approximately 30% of dogs with epilepsy remain poorly controlled on conventional AEDs, experiencing breakthrough seizures even at maximum medication doses. These refractory cases represent the greatest need for additional treatment options, and CBD has shown particular promise for dogs who don't achieve adequate control with conventional medications alone. Even for dogs with well-controlled epilepsy, the side effects of high-dose AEDs can significantly impact quality of life, and the potential to reduce medication doses while maintaining seizure control through CBD addition is an attractive goal.
How CBD Reduces Seizure Activity
CBD's anti-seizure effects occur through multiple mechanisms that collectively reduce neuronal excitability and raise seizure threshold. Unlike conventional anti-epileptic drugs that typically work through a single mechanism, CBD's multi-targeted approach may explain why it provides benefit even in dogs with refractory epilepsy who don't respond adequately to conventional medications.
Modulation of Neuronal Excitability
CBD affects multiple ion channels and receptors that control neuronal excitability. CBD activates TRPV1 receptors (transient receptor potential vanilloid 1), which are involved in regulating neuronal excitability and pain signaling. TRPV1 activation by CBD causes calcium influx into neurons, which paradoxically reduces neuronal excitability through desensitization mechanisms. A 2017 study in the Journal of Neuroscience demonstrated that CBD's anti-seizure effects were partially mediated through TRPV1 activation, and blocking TRPV1 reduced CBD's ability to suppress seizures in animal models.
CBD also modulates voltage-gated sodium channels, which are critical for action potential generation and propagation. By reducing sodium channel activity, CBD decreases the ability of neurons to fire rapidly and repetitively—the pattern seen during seizures. This mechanism is similar to how conventional AEDs like phenytoin work, though CBD's effects are more subtle and don't cause the same degree of sedation. Additionally, CBD affects T-type calcium channels, which are involved in generating abnormal electrical rhythms in the brain that can trigger seizures. By reducing T-type calcium channel activity, CBD may prevent the initiation of seizure activity in susceptible brain regions.
Enhancement of GABAergic Inhibition
GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter, and enhancing GABA signaling is a common mechanism of anti-epileptic drugs. CBD appears to enhance GABAergic inhibition through multiple pathways. CBD increases GABA levels in the brain by inhibiting GABA reuptake and metabolism, allowing GABA to remain in the synaptic cleft longer and produce stronger inhibitory effects. A 2018 study in Epilepsy Research found that CBD increased brain GABA concentrations in epileptic rats and that this increase correlated with seizure reduction.
CBD also appears to enhance the sensitivity of GABA receptors to GABA, making the inhibitory system more responsive. While the exact mechanism isn't fully understood, research suggests CBD may act as a positive allosteric modulator of GABA-A receptors, similar to how benzodiazepines work but without the same degree of sedation or tolerance development. This enhancement of GABAergic inhibition helps counterbalance the excessive excitation that drives seizure activity, raising the threshold for seizure initiation and propagation.
Anti-Inflammatory and Neuroprotective Effects
Inflammation in the brain plays an important role in epilepsy, both as a consequence of seizures (seizures cause inflammatory responses that can damage neurons) and as a contributor to ongoing seizure susceptibility (chronic inflammation lowers seizure threshold). CBD has potent anti-inflammatory effects in the brain, reducing production of pro-inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6 while increasing anti-inflammatory cytokines like IL-10. A 2016 study in Frontiers in Pharmacology demonstrated that CBD reduced neuroinflammation in epileptic animals and that this anti-inflammatory effect contributed to seizure reduction.
Beyond reducing inflammation, CBD has direct neuroprotective effects that may help prevent the brain damage that can result from recurrent seizures. CBD is a potent antioxidant, reducing oxidative stress and free radical damage to neurons. It also reduces excitotoxicity—the process by which excessive glutamate signaling damages and kills neurons. By protecting neurons from seizure-induced damage, CBD may help prevent the progressive worsening of epilepsy that can occur over time with poorly controlled seizures. While more research is needed to confirm these neuroprotective effects in dogs with epilepsy, the potential for CBD to not just reduce seizures but also protect the brain from seizure-related damage is an exciting possibility.
Veterinary researchers doing laboratory studies.
The Colorado State University Study: Landmark Research
The 2019 Colorado State University study, published in the Journal of the American Veterinary Medical Association, represents the first randomized, double-blind, placebo-controlled clinical trial of CBD for canine epilepsy and provides the strongest evidence for CBD's anti-seizure effects in dogs. Led by Dr. Stephanie McGrath, the study enrolled 26 dogs with idiopathic epilepsy who were already receiving conventional anti-epileptic medications (phenobarbital, potassium bromide, or both) but still experiencing at least two seizures per month despite treatment. This focus on dogs with inadequate seizure control on conventional medications is particularly relevant, as these are the dogs most in need of additional treatment options.
Study Design and Methodology
The study used a rigorous crossover design where each dog received both CBD oil and placebo oil in random order, with each treatment period lasting 12 weeks separated by a 4-week washout period. This design is particularly powerful because each dog serves as its own control, eliminating variability between individual dogs and allowing smaller sample sizes to detect meaningful effects. The CBD oil was administered at a dose of 2.5 mg per kilogram (approximately 1.1 mg per pound) twice daily, mixed with food. This dose was chosen based on preliminary pharmacokinetic studies showing it achieved therapeutic blood levels without causing significant side effects.
Throughout the study, owners maintained detailed seizure logs recording the date, time, duration, and severity of each seizure. Blood samples were collected at regular intervals to measure CBD blood levels, anti-epileptic drug levels (to ensure CBD wasn't causing dangerous increases in phenobarbital or bromide), and liver enzymes (to monitor for potential toxicity). Veterinarians performed neurological examinations at each visit to assess for side effects or changes in neurological status. The primary outcome measure was seizure frequency—the number of seizures per month during the CBD treatment period compared to the placebo period.
Key Findings and Results
The results were striking and clinically significant. Dogs receiving CBD experienced an average 33% reduction in seizure frequency compared to the placebo period, with 89% of dogs showing some degree of seizure reduction. This means nearly 9 out of 10 dogs benefited from CBD addition to their existing anti-epileptic regimen. The seizure reduction was statistically significant (p=0.004), meaning the results were very unlikely to be due to chance. Importantly, the degree of seizure reduction correlated with CBD blood levels—dogs with higher CBD concentrations in their blood experienced greater seizure reduction, supporting a dose-response relationship and suggesting that the effects were truly due to CBD rather than placebo effects.
The study also found that CBD was well-tolerated with minimal side effects. The most common side effect was mild sedation or lethargy, reported in approximately 30% of dogs, though this was often difficult to distinguish from the sedation caused by phenobarbital. A small number of dogs (about 15%) experienced mild elevation in liver enzymes (alkaline phosphatase), though these elevations were not clinically significant and resolved when CBD was discontinued. No dogs experienced serious adverse effects requiring withdrawal from the study. Importantly, CBD did increase blood levels of anti-epileptic drugs as expected—phenobarbital levels increased by an average of 20-30% when CBD was added—but this increase was predictable and manageable through dose adjustment.
A 33% average reduction in seizure frequency is clinically meaningful for dogs with epilepsy. For a dog experiencing 6 seizures per month, this translates to a reduction to 4 seizures per month—a significant improvement in quality of life for both dog and owner. For some dogs in the study, the reduction was even more dramatic, with seizure frequency decreasing by 50-80%. However, it's important to note that CBD did not eliminate seizures entirely in any dog, and some dogs showed minimal response. This variability in response is common with anti-epileptic treatments and highlights the importance of individualized treatment and realistic expectations.
The study had several limitations that should be acknowledged. The sample size was relatively small (26 dogs), limiting the ability to identify which dogs are most likely to benefit from CBD. The study duration was 12 weeks per treatment period, which is sufficient to assess short-term seizure reduction but doesn't address long-term efficacy or whether tolerance develops over time. All dogs in the study had idiopathic epilepsy, so the results may not apply to dogs with structural epilepsy or reactive seizures. The study used a specific CBD product at a specific dose, and results might differ with different products or dosing regimens. Despite these limitations, the Colorado State study provides the strongest evidence available for CBD's anti-seizure effects in dogs and serves as the foundation for evidence-based CBD protocols for canine epilepsy.
Pharmacokinetic Studies
Understanding how CBD is absorbed, distributed, metabolized, and eliminated in dogs is critical for developing effective dosing protocols. A 2018 pharmacokinetic study published in Frontiers in Veterinary Science examined CBD absorption and blood levels in healthy dogs receiving various doses of CBD oil. The study found that CBD was well-absorbed when given orally with food, with peak blood levels occurring 1-2 hours after administration. The half-life of CBD in dogs was approximately 4 hours, meaning blood levels decrease by half every 4 hours, which supports twice-daily dosing to maintain consistent blood levels.
The study also found that CBD absorption was significantly enhanced when given with fatty food compared to on an empty stomach—blood levels were 3-4 times higher when CBD was given with a meal containing fat. This finding has important practical implications: always give CBD with food, preferably a meal containing some fat, to maximize absorption and therapeutic effect. The pharmacokinetic data also showed that CBD blood levels were dose-proportional, meaning doubling the dose approximately doubled blood levels, which allows predictable dose adjustments when needed to achieve better seizure control.
Long-Term Safety Studies
A 2020 follow-up study from Colorado State University examined the long-term safety of CBD in dogs with epilepsy who continued CBD treatment for up to 1 year after the initial trial. The study found that CBD remained well-tolerated over extended periods, with no evidence of tolerance development (needing higher doses over time to maintain effects) or cumulative toxicity. Liver enzyme elevations, when they occurred, were mild and stable rather than progressive, and no dogs developed clinical signs of liver disease. This long-term safety data is reassuring for dogs who may need CBD treatment for years or even their entire lives.
The study also provided preliminary evidence that CBD's anti-seizure effects were maintained over time. While this wasn't a controlled trial (all dogs received CBD without a placebo comparison), seizure frequency remained reduced compared to pre-CBD baseline throughout the 1-year follow-up period. Some dogs even showed progressive improvement, with seizure frequency continuing to decrease over the first 6-12 months of treatment. This suggests that CBD's anti-seizure effects may build over time as brain inflammation decreases and neuroprotective effects accumulate, though more research is needed to confirm this possibility.
Clinical Experience and Case Reports
Beyond formal research studies, veterinary neurologists and general practitioners have accumulated extensive clinical experience using CBD for canine epilepsy. While case reports and clinical experience don't provide the same level of evidence as controlled trials, they offer valuable insights into real-world use and outcomes. Veterinarians report that CBD appears most effective for dogs with idiopathic epilepsy who have frequent seizures (multiple per month) despite conventional medication. Dogs with infrequent seizures (one every few months) may not show obvious benefit because the baseline seizure frequency is too low to detect meaningful reduction.
Clinical experience also suggests that CBD works best as an add-on therapy to conventional anti-epileptic drugs rather than as monotherapy. While some dogs with very mild epilepsy might achieve adequate control with CBD alone, most dogs with established epilepsy require conventional medications for baseline seizure control, with CBD providing additional benefit. The goal is typically not to replace phenobarbital or other AEDs but rather to improve seizure control beyond what conventional medications achieve alone, and potentially to reduce conventional medication doses and side effects while maintaining or improving seizure control.
Veterinarians also report variability in response time, with some dogs showing seizure reduction within 2-4 weeks while others require 8-12 weeks of consistent dosing before improvement becomes apparent. This variability likely reflects differences in underlying seizure mechanisms, baseline seizure frequency, and individual pharmacokinetics. The key is maintaining consistent dosing for at least 12 weeks before concluding that CBD is ineffective, as premature discontinuation may miss dogs who would eventually respond with longer treatment duration.
Beagle about to get his full spectrum CBD oil.
Starting Dose and Titration Schedule
The effective dose demonstrated in the Colorado State study was 2.5 mg per kilogram twice daily, which translates to approximately 1-1.2 mg per pound twice daily. For a 50-pound dog, this means 50-60mg of CBD twice daily (morning and evening), for a total daily dose of 100-120mg. This is significantly higher than doses typically used for anxiety (0.5-1 mg per pound once or twice daily) or pain (1-2 mg per pound twice daily), reflecting the higher doses required for seizure control. However, starting at the full target dose can cause excessive sedation, particularly when combined with phenobarbital or other sedating anti-epileptic drugs.
The recommended approach is to start low and titrate up gradually over 2-3 weeks. Begin with 0.5 mg per pound twice daily for the first week. This allows your dog to acclimate to CBD and minimizes initial sedation. For a 50-pound dog, this starting dose would be 25mg twice daily. After one week, if the starting dose is well-tolerated without excessive sedation, increase to 1 mg per pound twice daily (50mg twice daily for a 50-pound dog). Maintain this dose for 2-3 weeks while monitoring seizure frequency. If seizure control is inadequate and the dose is well-tolerated, increase to the target dose of 1.2 mg per pound twice daily (60mg twice daily for a 50-pound dog). Some dogs with refractory epilepsy may eventually need higher doses up to 2-3 mg per pound twice daily, but these increases should only be made under veterinary supervision with monitoring for side effects and drug interactions.
Timing and Administration
CBD can be given twice daily, approximately 12 hours apart, to maintain consistent blood levels throughout the day. The pharmacokinetic data showing a 4-hour half-life means that blood levels fluctuate significantly with once-daily dosing, potentially leaving periods of subtherapeutic levels when seizures are more likely to occur. Twice-daily dosing maintains more stable blood levels and provides more consistent seizure protection. Giving CBD with food, preferably meals containing some fat, to maximize absorption.
Consistency is critical for seizure control. Give CBD at the same times each day (for example, 8 AM and 8 PM) to maintain stable blood levels and establish a routine. Missing doses can lead to fluctuating blood levels and breakthrough seizures, so set reminders or integrate CBD administration into existing medication routines. If you miss a dose, give it as soon as you remember unless it's within 4 hours of the next scheduled dose, in which case skip the missed dose and resume the regular schedule. Don't double up doses to make up for missed doses, as this can cause excessive blood levels and increased side effects.
Monitoring Response and Adjusting Dose
Seizure frequency is the primary measure of CBD effectiveness, and maintaining a detailed seizure log is essential for objectively assessing response. Record the date, time, duration (in seconds or minutes), and type of each seizure (generalized tonic-clonic, focal, cluster). Also note any potential triggers (stress, missed medications, illness) and the post-ictal period duration and severity. This log allows you to calculate seizure frequency (seizures per month) before and after starting CBD and determine whether meaningful reduction has occurred.
Expect a timeline of 4-12 weeks before seeing meaningful seizure reduction. Some dogs respond within 2-4 weeks, but many require 8-12 weeks of consistent dosing before improvement becomes apparent. The Colorado State study evaluated dogs over 12 weeks, and seizure reduction was progressive throughout this period rather than immediate. If seizure frequency hasn't decreased after 12 weeks at the target dose (1-1.2 mg per pound twice daily), consider increasing to 1.5-2 mg per pound twice daily under veterinary supervision. If no improvement after 12 weeks at higher doses, CBD may not be effective for your dog's specific seizure type, and alternative treatments should be explored.
Beyond seizure frequency, monitor seizure severity and duration. Some dogs don't experience fewer seizures but have shorter, less severe seizures with faster recovery. This is still a meaningful improvement even if seizure frequency doesn't change. Also monitor quality of life factors including activity level, appetite, interaction with family, and overall demeanor. The goal is not just reducing seizures but improving your dog's overall well-being, and CBD's effects on anxiety, pain, and inflammation may provide quality of life benefits beyond seizure control.
Drug Interactions with Anti-Epileptic Medications
The most important consideration when using CBD for seizures is the interaction with conventional anti-epileptic drugs. CBD is metabolized by cytochrome P450 enzymes in the liver, the same enzyme system that processes most anti-epileptic medications. When CBD inhibits these enzymes, it can increase blood levels of concurrent medications, potentially leading to toxicity or enhanced side effects. Understanding and managing these interactions is critical for safe and effective use of CBD in dogs with epilepsy.
CBD and Phenobarbital Interaction
Phenobarbital is the most commonly used anti-epileptic drug in dogs, and the interaction with CBD is well-documented. The Colorado State study found that adding CBD increased phenobarbital blood levels by an average of 20-30%. This increase occurs because CBD inhibits the cytochrome P450 enzymes (particularly CYP2C9 and CYP2C19) that metabolize phenobarbital, causing phenobarbital to accumulate in the blood. While this interaction can be beneficial—allowing lower phenobarbital doses and reduced side effects while maintaining seizure control—it requires careful monitoring to prevent phenobarbital toxicity.
When adding CBD to a dog already taking phenobarbital, your veterinarian should check phenobarbital blood levels 2-4 weeks after starting CBD at the target dose. If phenobarbital levels are elevated above the therapeutic range (typically 15-40 mcg/mL, though ranges vary by laboratory), the phenobarbital dose should be reduced by 10-25% and levels rechecked in 2-3 weeks. Monitor for signs of phenobarbital toxicity including excessive sedation, ataxia (wobbliness), increased liver enzymes, or paradoxically increased seizure frequency (very high phenobarbital levels can actually increase seizures). Most dogs tolerate the modest increase in phenobarbital levels without problems, and some benefit from the enhanced phenobarbital effect, but monitoring is essential to ensure safety.
CBD and Potassium Bromide Interaction
Potassium bromide is often used as a second-line anti-epileptic drug or in combination with phenobarbital. The interaction between CBD and bromide is less well-studied than the phenobarbital interaction, but clinical experience suggests CBD can increase bromide blood levels by 15-25%. Bromide is not metabolized by liver enzymes but is eliminated by the kidneys, so the mechanism of interaction is different—CBD may affect renal bromide excretion or compete for protein binding, increasing free (active) bromide levels.
When adding CBD to a dog taking potassium bromide, monitor bromide blood levels 3-4 weeks after starting CBD. Bromide has a very long half-life (about 25 days in dogs), so it takes longer for levels to stabilize after CBD is added compared to phenobarbital. If bromide levels are elevated above the therapeutic range (typically 1-3 mg/mL), reduce the bromide dose by 10-20% and recheck levels in 3-4 weeks. Monitor for signs of bromide toxicity including severe sedation, ataxia, weakness, and in rare cases, bromide-induced pancreatitis. The interaction is generally manageable with dose adjustment, but close monitoring is essential.
CBD and Other Anti-Epileptic Drugs
For dogs taking levetiracetam (Keppra), zonisamide, or other newer anti-epileptic drugs, the interactions with CBD are less well-characterized. Levetiracetam is not significantly metabolized by cytochrome P450 enzymes, so the interaction with CBD should be minimal, though some clinical reports suggest CBD may modestly increase levetiracetam levels. Zonisamide is metabolized by CYP3A4, which CBD inhibits, so increased zonisamide levels are possible when CBD is added. For any anti-epileptic drug, inform your veterinarian that you're using CBD so they can monitor for signs of increased drug effects (excessive sedation, ataxia) and check blood levels if available.
The interaction between CBD and anti-epileptic drugs can actually be beneficial if managed properly. By increasing blood levels of conventional medications, CBD may allow dose reductions that decrease side effects while maintaining or improving seizure control. Some dogs eventually reduce their phenobarbital dose by 25-50% after adding CBD, experiencing fewer side effects (less sedation, less thirst and urination) while achieving better seizure control than with phenobarbital alone. However, any medication changes must be done gradually under veterinary supervision with careful monitoring of seizure frequency and drug levels.
If you have questions your Veterinary Professional is often one of your best resources.
Safety Considerations and Side Effects
CBD is generally well-tolerated in dogs with epilepsy, but the higher doses required for seizure control (compared to doses used for anxiety or pain) increase the risk of side effects. Understanding potential side effects and how to manage them ensures safe use of CBD as part of your dog's epilepsy treatment plan.
Common Side Effects
The most common side effect of CBD in dogs with epilepsy is sedation or lethargy, reported in approximately 30% of dogs in the Colorado State study. This sedation is often difficult to distinguish from the sedation caused by phenobarbital or other anti-epileptic drugs, and it typically improves over 1-2 weeks as tolerance develops. If sedation is excessive (your dog is difficult to rouse, won't eat, or can't walk normally), reduce the CBD dose by 25-30% and increase more gradually. Some sedation is acceptable and may even be beneficial if it reduces anxiety or improves sleep quality, but your dog should remain alert enough to eat, drink, and interact normally.
Mild elevation in liver enzymes, particularly alkaline phosphatase (ALP), occurs in approximately 15% of dogs receiving CBD. This is usually mild (less than 2-3 times the upper limit of normal) and doesn't indicate liver damage. However, because phenobarbital can also cause liver enzyme elevation and potential liver toxicity, monitoring liver enzymes is important when using CBD and phenobarbital together. Check liver enzymes before starting CBD, then 4-6 weeks after reaching the target dose, and every 3-6 months during long-term treatment. If liver enzymes are significantly elevated (more than 3-4 times normal) or progressively increasing, reduce the CBD dose or discontinue CBD and recheck enzymes in 2-3 weeks.
Gastrointestinal upset including decreased appetite, soft stool, or mild diarrhea can occur when starting CBD, particularly at higher doses. These effects are usually transient and resolve within a few days as your dog adjusts to CBD. Giving CBD with food helps minimize GI upset. If GI symptoms persist beyond one week or are severe (vomiting, complete loss of appetite, bloody diarrhea), reduce the dose or discontinue CBD and consult your veterinarian. Some dogs benefit from starting at very low doses (0.25 mg per pound twice daily) and increasing very gradually over 3-4 weeks to minimize GI side effects.
Serious Adverse Effects and When to Stop CBD
Serious adverse effects from CBD are rare but require immediate veterinary attention. Severe sedation where your dog cannot stand, won't eat or drink, or is unresponsive suggests excessive CBD levels or dangerous elevation of anti-epileptic drug levels. Discontinue CBD immediately and contact your veterinarian. Increased seizure frequency after starting CBD is uncommon but can occur if CBD is contaminated with THC (which can lower seizure threshold) or if the interaction with anti-epileptic drugs causes levels to become too high or too low. If seizures increase after starting CBD, discontinue CBD and consult your veterinarian to reassess the treatment plan.
Jaundice (yellowing of gums, whites of eyes, or skin) or signs of liver disease (vomiting, loss of appetite, increased thirst and urination, abdominal swelling) require immediate veterinary evaluation. While CBD-induced liver toxicity is rare, the combination of CBD with phenobarbital (which can cause liver damage) requires vigilance. Any signs of liver disease warrant immediate discontinuation of CBD and comprehensive liver evaluation including blood work and possibly ultrasound. Allergic reactions to CBD are extremely rare but can include facial swelling, hives, difficulty breathing, or collapse. These require emergency veterinary care and permanent discontinuation of CBD.
Working with Your Veterinarian
Adding CBD to your dog's epilepsy treatment should always be done in consultation with your veterinarian, preferably a veterinary neurologist if your dog has complex or refractory epilepsy. Before starting CBD, schedule a consultation to discuss your goals (reducing seizure frequency, reducing medication side effects, improving quality of life), review your dog's current medications and seizure history, establish baseline measurements including seizure frequency over the past 3-6 months, current anti-epileptic drug blood levels, and liver and kidney function tests. Your veterinarian can help determine whether CBD is appropriate for your dog's specific situation and develop a monitoring plan.
Once CBD treatment begins, maintain regular communication with your veterinarian. Schedule follow-up appointments at 4-6 weeks after starting CBD to check anti-epileptic drug blood levels and liver enzymes, assess seizure frequency and side effects, and adjust doses if needed. Continue monitoring every 3-6 months during long-term treatment to ensure seizure control is maintained and no cumulative toxicity develops. Share your seizure log at each visit so your veterinarian can objectively assess response. If seizure control deteriorates or new side effects develop, contact your veterinarian immediately rather than waiting for the next scheduled appointment.
Medication Tapering and Optimization
One of the most valuable potential benefits of adding CBD is the ability to reduce conventional anti-epileptic drug doses, decreasing side effects while maintaining or improving seizure control. However, medication tapering must be done extremely carefully under veterinary supervision, as abrupt reduction in anti-epileptic drugs can trigger severe seizure clusters or life-threatening status epilepticus. The general approach is to wait until CBD has been at the target dose for at least 8-12 weeks and seizure frequency has decreased by at least 30-50% before considering medication reduction. Never reduce anti-epileptic drugs during the initial CBD titration period or if seizure control is unstable.
When seizure control has improved and been stable for 2-3 months on CBD plus conventional medications, your veterinarian may recommend reducing the conventional medication dose by 10-25%. This reduction should be done gradually over 2-4 weeks while closely monitoring seizure frequency. If seizures remain controlled at the lower medication dose, maintain this regimen for 2-3 months before considering further reduction. If seizures increase, return to the previous medication dose and maintain CBD at the current level. Some dogs eventually achieve adequate control on CBD plus low-dose conventional medication (25-50% of the original dose), while others require full-dose conventional medication plus CBD for optimal control. The goal is finding the minimum medication burden that maintains acceptable seizure control and quality of life.
Lifestyle and Environmental Management
Beyond medications and supplements, lifestyle and environmental factors significantly impact seizure control. Maintain consistent routines including feeding times, medication times, exercise schedules, and sleep patterns, as disruptions to routine can trigger seizures in some dogs. Ensure adequate sleep, as sleep deprivation lowers seizure threshold. Manage stress through environmental enrichment, positive reinforcement training, and avoiding known stressors when possible. Some dogs have identifiable seizure triggers like specific foods, environmental allergens, or stressful situations—identifying and avoiding these triggers can reduce seizure frequency independent of medication effects.
Nutrition plays an important role in epilepsy management. Some dogs benefit from ketogenic diets (high fat, low carbohydrate) which have anti-seizure effects, though these specialized diets should only be used under veterinary supervision. Ensure adequate intake of omega-3 fatty acids (fish oil) which have anti-inflammatory and neuroprotective effects that may complement CBD. Avoid foods or supplements that might lower seizure threshold including high doses of rosemary (a common preservative in dog foods that can be pro-convulsant at high levels), and certain essential oils. Maintain stable blood sugar through regular feeding schedules, as hypoglycemia can trigger seizures.
Long-Term Management and Expectations
Epilepsy is typically a lifelong condition requiring ongoing management, and understanding what to expect with long-term CBD use helps set realistic goals and maintain commitment to treatment.
Realistic Goals and Success Metrics
The goal of epilepsy treatment is not necessarily complete seizure freedom, though this is achieved in some dogs. More realistic goals for most dogs with epilepsy include reducing seizure frequency by 50% or more, reducing seizure severity and duration, extending the time between seizures (increasing the seizure-free interval), reducing anti-epileptic drug doses and side effects, and improving overall quality of life.
Success should be measured not just by seizure frequency but by overall quality of life. A dog who has the same number of seizures but shorter, less severe seizures with faster recovery has experienced meaningful improvement. A dog who has slightly fewer seizures but is more alert, active, and engaged due to reduced medication side effects has also benefited significantly. Track multiple metrics including seizure frequency, seizure duration and severity, post-ictal period duration and severity, medication doses and side effects, activity level and engagement, and overall quality of life to get a complete picture of treatment success.
Duration of Treatment and Discontinuation
Most dogs with epilepsy require lifelong treatment, and CBD should be viewed as a long-term commitment rather than a short-term intervention. The Colorado State follow-up study showed that CBD remained effective and well-tolerated for at least one year, and clinical experience suggests many dogs continue to benefit for years. There's no evidence that CBD loses effectiveness over time (tolerance development), though individual dogs may experience fluctuations in seizure control due to other factors like stress, illness, or progression of underlying disease.
If you need to discontinue CBD (due to cost, side effects, or lack of efficacy), taper gradually rather than stopping abruptly. Reduce the dose by 25% every 1-2 weeks while monitoring seizure frequency closely. Abrupt CBD discontinuation could potentially trigger breakthrough seizures, particularly if anti-epileptic drug doses have been reduced during CBD treatment. If seizures increase during CBD tapering, slow the taper or return to the previous dose and consult your veterinarian about alternative approaches. Never discontinue conventional anti-epileptic drugs abruptly, even if CBD is continued, as this can trigger life-threatening status epilepticus.
Australian Shepard resting peacefully while owner is reviewing medications.
The Bottom Line: CBD as Part of Epilepsy Management
CBD represents a valuable addition to the treatment arsenal for canine epilepsy, offering meaningful seizure reduction for the majority of dogs when used as an adjunct to conventional anti-epileptic medications. The evidence supporting CBD's use for seizures is stronger than for most other canine conditions, with the Colorado State University study providing rigorous, controlled data demonstrating 33% average seizure reduction and 89% response rate. This level of evidence, combined with CBD's favorable safety profile and potential to reduce reliance on medications with significant side effects, makes CBD worth serious consideration for most dogs with epilepsy, particularly those with inadequate seizure control on conventional medications alone.
The key to success with CBD for seizures is appropriate expectations, evidence-based dosing, and integration into comprehensive epilepsy management. CBD is not a cure for epilepsy and will not eliminate seizures in most dogs, but a 30-50% reduction in seizure frequency represents a meaningful improvement in quality of life for both dog and owner. The higher doses required for seizure control (1-2 mg per pound twice daily) compared to other conditions, the 4-12 week timeline for effects, and the critical importance of twice-daily dosing and consistency must be understood and committed to for CBD to work effectively. The interactions with conventional anti-epileptic drugs require veterinary supervision and monitoring, but these interactions can be managed safely and may even be beneficial if they allow medication dose reductions.
For dogs with idiopathic epilepsy experiencing frequent seizures despite conventional medication, CBD offers strong evidence of benefit with minimal risk. For dogs with well-controlled epilepsy on conventional medications, CBD may allow medication dose reductions that improve quality of life by reducing side effects. For dogs with refractory epilepsy who have failed multiple conventional medications, CBD provides hope for improved control when added to existing treatment regimens. The decision to use CBD should be made in consultation with your veterinarian, with realistic goals, commitment to consistent dosing and monitoring, and understanding that CBD is one component of comprehensive epilepsy management rather than a standalone solution. With appropriate use, CBD can help many dogs with epilepsy achieve better seizure control, reduced medication burden, and improved quality of life.
Boost the Endocannabinoid System →
Medical Disclaimer: This article is for informational purposes only and does not constitute veterinary medical advice. Epilepsy is a serious neurological condition requiring veterinary diagnosis and treatment. Always consult with a licensed veterinarian before starting CBD or making any changes to your dog's seizure medications. Never discontinue anti-epileptic drugs without veterinary supervision as this can trigger life-threatening seizures. The author and VetsGrade are not liable for any treatment decisions made based on this information.
